PCM
PASG icon

Prelude Capital Management’s Passage Bio PASG Stock Holding History

Prelude Capital Management’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-620
Closed -$16K – 1539
2022
Q3 		$16K Sell
620
-637
-51% -$25.1K ﹤0.01% 1284
2022
Q2 		$59K Buy
1,257
+527
+72% +$24.6K ﹤0.01% 1471
2022
Q1 		$45K Buy
+730
New +$60.2K ﹤0.01% 1497

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Prelude Capital Management's PASG Position: Q4 2022 in Review

Prelude Capital Management sold out of Passage Bio (PASG) in Q4 2022, closing a stake of 620 shares — an estimated $16K sold.

Prelude Capital Management first reported a position in PASG in Q1 2022 and held it in 3 quarters. The position peaked at $59K in Q2 2022. 67 funds tracked by Wall St. Rank hold PASG as of Q4 2022.

  • Prelude Capital Management reported no remaining Passage Bio position as of Q4 2022 after selling out during the quarter.
  • Prelude Capital Management sold 620 Passage Bio shares in Q4 2022, an estimated $16K.
  • Prelude Capital Management first reported a position in Passage Bio in Q1 2022 and held it in 3 quarters.
  • Prelude Capital Management's Passage Bio position peaked at $59K in Q2 2022.
  • 67 funds tracked by Wall St. Rank held Passage Bio as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.